Drugs, gums or patches won't increase your chances of quitting

January 9, 2018 by Simon Chapman, The Conversation
Drugs don’t give you an edge over quitting cold turkey. Credit: Shutterstock/shanon mungmee

Using prescription drugs or over-the-counter products like gums, mints or patches won't increase your chances of quitting smoking a year later, according to a new study.

The US researchers followed two groups of people 2002/03 and 2010/11 and found at the end of the 12-month period, those using varenicline (sold in Australia as Champix), bupropion (Zyban), or nicotine-replacement therapy (gums, mints or patches) were no more likely to have quit for 30 days or more than those who didn't use these drugs.

Evidence based smoking cessation?

We're told the best way to quit smoking is to use an "evidence-based" method: a strategy supported by high-quality research evidence. And for the last 30 or so years, this has been nicotine-replacement therapy, bupropion (Zyban) and varenicline (Champix), which claim to increase (and sometimes double) your chance of success.

In the hierarchy of evidence, the lowest form is anecdote or case studies ("I smoked for 20 years, then an alternative therapist sprinkled magic powder on me, and the next day I stopped smoking!"). These cannot withstand the most elementary critical appraisal, starting with the basic question of how many similar smokers sprinkled with the powder kept smoking and how many who went nowhere it also stopped smoking.

Far higher up the evidence pyramid is the double-blinded, randomised controlled trial (RCTs). In these, both the person taking the treatment and those delivering it are unware of who is taking the active drug and who is taking the comparison placebo or comparison drug. All enrolled in RCTs are randomly allocated to the active or placebo/comparison groups. The numbers of participants are sufficiently large enough to allow for an outcome to be declared statistically significant (or not) above a chance finding.

Some have tried to dismiss earlier findings about the poor performance of nicotine-replacement therapy by emphasising "indication bias". In the real world, those who opt to use medications to try to quit are likely to be more intractable smokers, more highly addicted to nicotine, and with histories of failure at quitting unaided. No one should therefore be surprised if they fail more often than those who try to quit on their own.

In this new study, this issue was anticipated and all smokers were assessed by what the study authors called a "propensity to quit" score. This score accounts for factors such as smoking intensity, nicotine dependence, their quitting history, self-efficacy to quit, and whether they lived in a smoke-free home where quitting would likely be more supported.

In the analysis, those who tried to quit with drugs and those who didn't were matched on this , so "like with like" could be compared in the analysis. The findings held even when these "propensity" to quit factors were taken into account.

RCTs are very different to real world use

Critics have long pointed out that RCTs have many features which make them a pale shadow of how drugs are used in the real world.

RCTs often exclude people with mental illness, poor English, and no fixed address. Excluding hard-to-reach and treat participants is likely to produce more flattering results.

In the real world, people are not paid or otherwise incentivised to keep taking the drugs across the full period of the trial, so compliance is almost always far lower.

In the real world, people do not get reminder calls, texts or visits from researchers highly motivated to minimise trial drop-out. There is no "Hawthorne effect": when trial involvement and the attention paid to participants alters the outcomes.

Nicotine-addicted people generally know very quickly if they have been allocated to the placebo arm in NRT trials because their brains feel deprived of nicotine. They invariably experience unpleasant symptoms. Knowing they have been allocated to the placebo undermines the integrity of the trial because it is important participants believe the drug might be effective.

Large, studies like the one just published, which assess long-term success, not just end-of-treatment or short-term results, are therefore of most importance in assessing effectiveness. These new data ought to cause such rhetoric to cool right down.

As for the evidence on e-cigarettes in quitting, neither the US Preventive Health Services Task Force, nor the UK's National Institute for Health and Care Excellence or Australia's National Health and Medical Research Council, have endorsed e-cigarettes as an effective way of quitting smoking.

Quitting smoking is the single most important thing anyone can do to reduce the likelihood they will get heart or lung disease, and a whole string of cancers.

It has been in the clear interests of the pharmaceutical and, more recently, the vaping (e-cigarette) industries, to promote the notion that anyone who tries to quit alone is the equivalent of someone with pneumonia refusing antibiotics. Hundreds of millions around the world have quit smoking without using any pharmaceutical intervention.

Before nicotine-replacement therapies became available in the 1980s, many millions of smokers successfully quit smoking without using any or nicotine substitute. The same still happens today: most ex-smokers quit by going cold turkey.

The problem is, in recent years, the government has moth-balled the national quit campaign, the megaphone for promoting this very positive message. Commercial interests are now commodifying something millions have always done for themselves.

Explore further: Study finds differing treatment options for women smokers

Related Stories

Study finds differing treatment options for women smokers

July 13, 2016
A new study led by Assistant Medical Professor Philip Smith of The City College of New York's Sophie Davis Biomedical Education/CUNY School of Medicine, and conducted in collaboration with researchers at Yale University and ...

Smokers with depression try to quit more often but find it harder

February 18, 2016
People diagnosed with depression are about twice as likely to smoke as the general population. A survey of 6811 participants from Australia, Canada, the United Kingdom, and the USA, published today in the scientific journal ...

Novel nicotine inhaler doubles smoking quit rates

May 17, 2016
A study by researchers at the University of Otago, Wellington shows that smokers who used a nicotine inhaler were twice as likely to quit smoking as smokers using a placebo inhaler.

Helping smokers quit: Payments, personalized support can work

October 30, 2017
Money can be more powerful than nicotine, as a new study found that smokers who received financial incentives, in addition to personalized support, to help them quit were more successful than smokers who did not receive these ...

Study finds that smokers who try e-cigarettes to quit are younger and more motivated to quit

July 23, 2013
University of Hawaii Cancer Center Prevention and Control Program researchers Pallav Pokhrel, PhD and Thaddeus Herzog, PhD have found that smokers who use e-cigarettes as a tool to stop smoking tend to be younger and more ...

Progressively reducing the nicotine content of cigarettes may not lead smokers to quit

July 22, 2015
The US Family Smoking Prevention and Tobacco Control Act, passed in 2009, permits the U.S. Food and Drug Administration (FDA) to set standards for cigarette nicotine content. The FDA is accordingly supporting research into ...

Recommended for you

Self-lubricating latex could boost condom use: study

October 17, 2018
A perpetually unctuous, self-lubricating latex developed by a team of scientists in Boston could boost the use of condoms, they reported Wednesday in the journal Royal Society Open Science.

How healthy will we be in 2040?

October 17, 2018
A new scientific study of forecasts and alternative scenarios for life expectancy and major causes of death in 2040 shows all countries are likely to experience at least a slight increase in lifespans. In contrast, one scenario ...

Study finds evidence of intergenerational transmission of trauma among ex-POWs from the Civil War

October 16, 2018
A trio of researchers affiliated with the National Bureau of Economic Research has found evidence that suggests men who were traumatized while POWs during the U.S. Civil War transmitted that trauma to their offspring—many ...

Father's nicotine use can cause cognitive problems in children and grandchildren

October 16, 2018
A father's exposure to nicotine may cause cognitive deficits in his children and even grandchildren, according to a study in mice publishing on October 16 in the open-access journal PLOS Biology by Pradeep Bhide of Florida ...

Many supplements contain unapproved, dangerous ingredients: study

October 13, 2018
(HealthDay)—U.S. health officials have issued more than 700 warnings during the last decade about the sale of dietary supplements that contain unapproved and potentially dangerous drug ingredients, new research reveals.

Age at which women experience their first period is linked to their sons' age at puberty

October 12, 2018
The age at which young women experience their first menstrual bleeding is linked to the age at which their sons start puberty, according to the largest study to investigate this association in both sons and daughters.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.